Weekly PTH Dosing for Osteoporosis Bone Density and Fracture Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis using parathyroid hormone (PTH) are not safe and effective, particularly in preventing bone fractures, as they often lead to hypercalcemia and do not adequately address bone strength and fracture risk.
Innovation Solution
Administering PTH once a week in a unit dose of 200 units to patients with mild or moderate renal dysfunction, aged 65 or older, and with prevalent bone fractures and low bone density, in combination with calcium and vitamin D, to enhance bone density and prevent fractures without causing hypercalcemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If PTH is administered daily or frequently to increase bone density, then bone density increases, but hypercalcemia occurs as an adverse reaction
Solution Approach 1:
The patent applies periodic action by administering PTH once weekly instead of daily or frequently. This intermittent dosing schedule allows the body to respond to PTH stimulation while having sufficient intervals for calcium homeostasis to reset, thereby achieving bone density improvement without triggering persistent hypercalcemia. The weekly administration cycle creates a rhythm of bone formation stimulation followed by physiological normalization.
Solution Approach 2:
The patent changes the dosing parameters from frequent/daily administration to once-weekly administration at a specific unit dose of 200 units. This parameter modification fundamentally alters the pharmacokinetic and pharmacodynamic profile of PTH, transforming it from a continuous stimulus that causes hypercalcemia to a pulsed stimulus that promotes bone formation while allowing calcium levels to remain stable between doses.
2Quantity of substance
If PTH is administered to increase bone density, then bone density increases, but the effect on bone strength and fracture risk prevention is not demonstrated
Solution Approach 1:
The patent incorporates feedback mechanisms by establishing clear inclusion criteria (age 65 or older, prevalent bone fractures, bone density less than 80% of young adult mean) and monitoring parameters (serum calcium levels, bone density measurements, fracture occurrence). This feedback loop allows optimization of the treatment regimen to ensure both bone density improvement and fracture prevention, with the ability to adjust or discontinue treatment based on observed outcomes and adverse events.
Solution Approach 2:
The patent applies preliminary action by selecting patients who meet specific high-risk criteria before initiating treatment. By pre-identifying patients with prevalent bone fractures and significantly reduced bone density, the treatment protocol ensures that PTH administration is targeted at those most likely to benefit from fracture prevention, thereby demonstrating efficacy in the population most vulnerable to osteoporotic fractures.
3Productivity
If PTH is administered at higher doses or more frequently to improve efficacy, then bone density increases faster, but safety decreases due to hypercalcemia
Solution Approach 1:
The patent applies partial action by using a moderate dose of 200 units administered once weekly, which is sufficient to stimulate bone formation but not excessive enough to cause hypercalcemia. This optimized dosing strategy achieves the minimum effective action needed to improve bone density while staying below the threshold that triggers harmful calcium elevation, thereby balancing productivity and safety.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
[Object] To provide a method of treating osteoporosis by PTH that has excellent safety and high efficacy. To provide a method for inhibiting/preventing bone fractures by PTH that has excellent safety. And to provide a drug to do this. [Means of Achievement] A drug containing PTH as the active ingredient, characterized in that a unit dose of PTH of 200 units is administered weekly in the above method.